Liquidia Corporation

Liquidia Corporation

LQDA·NASDAQ

$55.69

+1.5%
HealthcareBiotechnology

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

At a Glance

Live Snapshot
Market Cap$4.95B
EPS-0.8000
P/E Ratio-69.61
Earnings Date08/11/2026

lqda

Total Other Income Expenses Net

Last Annual Value

-17.55M

3-Year CAGR

-98%

5-Year CAGR

-92%

10-Year CAGR

-74%

Liquidia Corporation

Liquidia Corporation Competitors Analysis of Total Other Income Expenses Net

LQDA · NASDAQ
CompanyTotal Other Income Expenses Net
CAGR 3Y
CAGR 5Y
CAGR 10Y
-17.55M
N/AN/AN/A 
4.43M
-34.5%6.2%16.7%
146.51M
122.0%N/AN/A
42.90M
-5.9%56.3%49.3%
ETNB logo
89bio, Inc.
NASDAQ:ETNB
18.27M
12.4%N/AN/A
-95.58M
N/AN/AN/A
33.00M
-5.4%101.2%65.7%
4.08M
35.3%-43.6%N/A
58.34M
14.0%21.6%36.9%
Liquidia Corporation

Liquidia Corporation Fair Value Envelope

LQDA · NASDAQ

Our analysis suggests that LQDA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $55.69, this represents a potential HIDDEN relative to our calculated worth for Liquidia Corporation.

Intrinsic Value
Current Price: $55.69